Cure My Disease

Don't miss your cure!

 Log in / Sign up

Genetic blueprint of tumors may guide smarter cancer treatment

NCT ID NCT07713550

Knowledge-focused Sponsor: The Belgian Society of Medical Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks at whether detailed genetic testing of tumor tissue or blood can help doctors make better treatment decisions for people with advanced solid tumors or primary brain cancers. About 550 participants will have their tumors genetically profiled, and a smaller group without available tissue will have blood-based testing. The goal is to see how often this information leads to a recommended targeted therapy and whether doctors follow those recommendations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
comprehensive genomic profiling (CGP) via tissue or liquid biopsy
What this could lead to
If successful, this could show that routine genomic profiling helps doctors choose more effective, personalized treatments for advanced cancers.
What could go wrong
This is an observational study, not a treatment trial. It may not prove that profiling improves outcomes, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 550 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

550 consecutive patients with metastatic solid tumors that are eligible for a systemic therapy recruited on a first come first serve basis. 500 patients will be tested on a tissue biopsy and 50 patients will be tested on a liquid biopsy when tissue biopsy is not available or feasible for safety reason.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patient (minimum 18 years) able to provide written informed consent for GeNeo 2.0. 2. ECOG Performance status ≤2 3. Patients with advanced solid tumors or primary CNS tumors that are candidates for systemic anticancer therapy and open for enrollment in a potential downstream therapeutic trial. Enrollment in early treatment lines is strongly encouraged Tumor cohorts of breast cancer and lung cancer will be prioritized, with a minimum cap of 100 for each tumor type. Recruitment for all other tumor type cohorts will be capped at a maximum of 40 patients per tumor type. The MTB can decide on prematurely closing or extending tumor type cohorts based on treatment recommendations, clinical trial landscape or downstream treatment options. Enrollment of patients early in the advanced treatment setting will be strongly encouraged. 4. Patients should have archived tissue available from a metastatic (preferred) or primary lesion biopsy for comprehensive profiling. The tissue should not be more than 2 years-old and fixed in 10% neutral buffered formalin. Tumor cell content should be \>20% Exclusion Criteria: 1. Life expectancy of ≤12 weeks according to the local investigator 2. Clinically significant hematopoietic, renal and/or hepatic dysfunction, according to the local investigator, which would make them ineligible for MGTO therapy 3. Patients unwilling to comply with GeNeo 2.0 protocol data collection, data sharing and other study procedures 4. Patients unwilling to provide informed consent and comply with study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer central nervous system neoplasm metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumor cancer Primary CNS tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Klina

    RECRUITING

    Brasschaat, 2930, Belgium

  • CHU Liège Sart Tilman

    RECRUITING

    Liège, 4000, Belgium

  • CHU UCL Namur

    RECRUITING

    Namur, 5000, Belgium

  • GHDC

    RECRUITING

    Gilly, 6060, Belgium

  • Imelda

    RECRUITING

    Bonheiden, 2820, Belgium

  • Institute Jules Bordet

    RECRUITING

    Anderlecht, 1070, Belgium

  • Jessa Ziekenhuis

    RECRUITING

    Hasselt, 3500, Belgium

  • Les Cliniques Universitaires St Luc

    RECRUITING

    Woluwe-Saint-Lambert, 1200, Belgium

  • UZ Brussel

    RECRUITING

    Jette, 1090, Belgium

  • UZ Gent

    RECRUITING

    Ghent, 9000, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • Universitaire Ziekenhuis Antwerpen

    RECRUITING

    Edegem, 2650, Belgium

  • VITAZ

    RECRUITING

    Sint-Niklaas, 9100, Belgium

  • ZAS

    RECRUITING

    Antwerp, 2030, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.